IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack
A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 160 participants.
Also called NCT06139328
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 160 participants
- Sponsor
- Registry
-
NCT06139328
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Australia, Canada, Czechia, Germany, Hungary, Italy, New Zealand, Poland, Singapore, Slovakia, South Korea, Spain, Taiwan, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT06139328. Randomized; triple masking; primary purpose treatment. Start 2023-12-05 (actual); primary completion 2025-09-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack
- Acronym
- IRI-EXPLORE
- Condition
- Myocardial Infarction
- Intervention (Drug)
- BI 765845
- Intervention (Drug)
- Placebo matching BI 765845
- Lead sponsor
- Boehringer Ingelheim
Record details
- Record id
cardio:ct-nct06139328- Content hash
20bcd4b4f021d666768d7d5bf00399cb271d4e3a7bcf95d2d42b7594cbaab590